Ebi Hiromichi 衣斐寛倫

… Alternative Names

EBI Hiromichi 衣斐寛倫

Less

Researcher Number	00645145
Other IDs	https://orcid.org/0000-0003-3155-7576
Affiliation (Current)	2024: 愛知県がんセンター(研究所), がん標的治療TR分野, 分野長
Affiliation (based on the past Project Information) *help	2018 – 2024: 愛知県がんセンター(研究所), がん標的治療TR分野, 分野長 2017: 愛知県がんセンター(研究所), 腫瘍病理学部, 部長 2015 – 2016: 金沢大学, がん進展制御研究所, 准教授 2013 – 2015: 金沢大学, がん進展制御研究所, 助教
Review Section/Research Field	Principal Investigator Tumor therapeutics / Basic Section 50010:Tumor biology-related / Medium-sized Section 50:Oncology and related fields / Basic Section 50020:Tumor diagnostics and therapeutics-related Except Principal Investigator Basic Section 62010:Life, health and medical informatics-related / Respiratory organ internal medicine / Biological Sciences
Keywords	Principal Investigator KRAS / 癌 / 上皮間葉移行 / 分子標的薬耐性 / フィードバック / トランスレーショナルリサーチ / BRAF / SHP2 / MEK / シグナル伝達 … More / 局在変化 / 膜タンパク / オンコメタボライト / 耐性 / metabolite / tumor agonistic therapy / BRAF変異 / 臓器多様性 / 個別化治療 / サブタイプ / tumor agonistic / 機能解析 / 獲得変異 / クラス分類 / molecular classification / mutation / 腫瘍不均一性 / 肺がん / FGFR1 / feedback / EMT / ERKシグナル / PI3キナーゼ / MEK阻害薬 / MEK阻害剤 / がん / スクリーニング / MAPK / 受容体 / フィードバック機構 … More Except Principal Investigator 肺がん / 分子標的薬耐性 / ネットワーク推定 / シングルセルデータ解析 / ネットワーク / 説明可能AI / 一細胞計測 / ボリノスタット / 個別化医療 / mTOR阻害薬 / EGFR阻害薬耐性 / BIM遺伝子多型 / ALK阻害薬耐性 / がん性髄膜炎 / がん性胸水 / イメージング / 転移 / がん性胸膜炎 / 骨転移 / 脳転移 / EGFR / 腫瘍血管 / PDGFR / FGFR1 / ALK-TKI / EGFR-TKI / 血管新生 / 線維芽細胞 / 腫瘍 / Met / ヒストン脱メチル化酵素 / 分子標的薬 / 薬剤耐性 / EMT / 胸膜中皮腫 / EGFRリガンド / HGF / ALK阻害薬 / 中皮腫 / ALK肺がん / EGFR変異肺がん / 微小環境 Less

Role of protein localization in the resistance mechanism to molecular targeted drugsPrincipal Investigator
- Principal Investigator
  
  衣斐寛倫
- Project Period (FY)
  2024 – 2026
- Research Category
  
  Grant-in-Aid for Scientific Research (B)
- Review Section
  
  Basic Section 50010:Tumor biology-related
- Research Institution
  Aichi Cancer Center Research Institute
Elucidation of the role of oncometabolite in the resistance mechanism of molecular targeted therapyPrincipal Investigator
- Principal Investigator
  
  衣斐寛倫
- Project Period (FY)
  2022 – 2024
- Research Category
  
  Grant-in-Aid for Challenging Research (Exploratory)
- Review Section
  
  Medium-sized Section 50:Oncology and related fields
- Research Institution
  Aichi Cancer Center Research Institute
説明可能AIによる１細胞計測大規模ネットワークデータからの知識発見技術の開発
- Principal Investigator
  
  山口類
- Project Period (FY)
  2022 – 2024
- Research Category
  
  Grant-in-Aid for Scientific Research (B)
- Review Section
  
  Basic Section 62010:Life, health and medical informatics-related
- Research Institution
  Aichi Cancer Center Research Institute
Tumor agonistic and tissue specific role of BRAF mutations in cancerPrincipal Investigator
- Principal Investigator
  
  Ebi Hiromichi
- Project Period (FY)
  2020 – 2022
- Research Category
  
  Grant-in-Aid for Scientific Research (B)
- Review Section
  
  Basic Section 50020:Tumor diagnostics and therapeutics-related
- Research Institution
  Aichi Cancer Center Research Institute
Develop novel therapeutics against KRAS mutant cancer by regulating PI3K and ERK signal(Fostering Joint International Research)Principal Investigator
- Principal Investigator
  
  Ebi Hiromichi
- Project Period (FY)
  2016 – 2019
- Research Category
  
  Fund for the Promotion of Joint International Research (Fostering Joint International Research)
- Research Field
  
  Tumor therapeutics
- Research Institution
  Aichi Cancer Center Research Institute
  Kanazawa University
Development of target therapy against KRAS mutant lung cancer stratified by EMT status.Principal Investigator
- Principal Investigator
  
  EBI Hiromichi
- Project Period (FY)
  2016 – 2018
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Research Field
  
  Tumor therapeutics
- Research Institution
  Aichi Cancer Center Research Institute
  Kanazawa University
Development of treatment strategy against KRAS mutant cancer by targeting PI3K and ERKPrincipal Investigator
- Principal Investigator
  
  Hiromichi Ebi
- Project Period (FY)
  2014 – 2015
- Research Category
  
  Grant-in-Aid for Young Scientists (B)
- Research Field
  
  Tumor therapeutics
- Research Institution
  Kanazawa University
Study to overcome metastasis and targeted drug-resistance of lung cancer
- Principal Investigator
  
  YANO Seiji
- Project Period (FY)
  2012 – 2014
- Research Category
  
  Grant-in-Aid for Scientific Research (B)
- Research Field
  
  Respiratory organ internal medicine
- Research Institution
  Kanazawa University
Development of novel therapy targeting microenvironment in respiratory malignancy
- Principal Investigator
  
  YANO Seiji
- Project Period (FY)
  2010 – 2014
- Research Category
  
  Grant-in-Aid for Scientific Research on Innovative Areas (Research in a proposed research area)
- Review Section
  
  Biological Sciences
- Research Institution
  Kanazawa University

All 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

All Journal Article Presentation Book Patent

[Book] 分子呼吸器病2017
- Author(s)
  衣斐寛倫
- Total Pages
  3
- Publisher
  先端医学社
- Data Source
  KAKENHI-PROJECT-16K07164
[Book] 分子呼吸器病2017
- Author(s)
  衣斐寛倫
- Total Pages
  3
- Publisher
  先端医学社
- Data Source
  KAKENHI-PROJECT-15KK0303
[Book] 腫瘍内科2016
- Author(s)
  衣斐寛倫
- Total Pages
  5
- Publisher
  科学評論社
- Data Source
  KAKENHI-PROJECT-16K07164
[Book] 臨床消化器内科2016
- Author(s)
  衣斐寛倫、矢野聖二
- Total Pages
  5
- Publisher
  日本メディカルセンター
- Data Source
  KAKENHI-PROJECT-16K07164
[Book] 日本胸部臨床2015
- Author(s)
  衣斐寛倫
- Total Pages
  10
- Publisher
  克誠堂出版株式会社
- Data Source
  KAKENHI-PROJECT-26830105
[Book] 医学のあゆみ2015
- Author(s)
  衣斐寛倫
- Total Pages
  5
- Publisher
  医歯薬出版株式会社
- Data Source
  KAKENHI-PROJECT-26830105
[Book] 実験医学増刊2015
- Author(s)
  衣斐寛倫
- Total Pages
  6
- Publisher
  羊土社
- Data Source
  KAKENHI-PROJECT-26830105
[Journal Article] Drug-Tolerant Persister Cells After EGFR Tyrosine Kinase Inhibitor Treatment: Their Origin and the Influences From the Tumor Microenvironment2023
- Author(s)
  Ebi Hiromichi
- Journal Title
  
  Journal of Thoracic Oncology
  
  Volume: 18 Issue: 4 Pages: 399-401
- DOI
  10.1016/j.jtho.2022.12.010
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-20H03542
[Journal Article] ARAF protein kinase activates RAS by antagonizing its binding to RASGAP NF12022
- Author(s)
  Su W、Mukherjee R、Yaeger R、Son J、Xu J、Na N、Merna TN、Hechtman J、Paroder V、Lin M、Mattar M、Qiu J、Chang Q、Zhao H、Zhang J、Little M、Adachi Y、Han SW、Taylor BS.、Ebi H、Abdel-Wahab O、de Stanchina E、Rudin CM.、Janne PA.、McCormick F、Yao Z、Rosen N.
- Journal Title
  
  Molecular Cell
  
  Volume: 82 Issue: 13 Pages: 2443-2457.e7
- DOI
  10.1016/j.molcel.2022.04.034
- Peer Reviewed / Open Access / Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-20H03542
[Journal Article] MAPK経路、がんゲノム医療時代の分子腫瘍学2022
- Author(s)
  1.衣斐寛倫
- Journal Title
  
  病理と臨床
  
  Volume: 40 Pages: 092-095
- Data Source
  KAKENHI-PROJECT-20H03542
[Journal Article] High-risk neuroblastoma with NF1 loss of function is targetable using SHP2 inhibition2022
- Author(s)
  Cai J、Jacob S、Kurupi R、Dalton KM.、Coon C、Greninger P、Egan RK.、Stein GT.、Murchie E、McClanaghan J、Adachi Y、Hirade K、Dozmorov M、Glod J、Boikos SA.、Ebi H、Hao H、Caponigro G、Benes CH.、Faber AC.
- Journal Title
  
  Cell Reports
  
  Volume: 40 Issue: 4 Pages: 111095-111095
- DOI
  10.1016/j.celrep.2022.111095
- Peer Reviewed / Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-20H03542
[Journal Article] TGF-β-dependent reprogramming of amino acid metabolism induces epithelial?mesenchymal transition in non-small cell lung cancers2021
- Author(s)
  Nakasuka Fumie, Tabata Sho, Sakamoto Takeharu, Hirayama Akiyoshi, Ebi Hiromichi, Yamada Tadaaki, Umetsu Ko, Ohishi Maki, Ueno Ayano, Goto Hisatsugu, Sugimoto Masahiro, Nishioka Yasuhiko, Yamada Yasuhiro, Tomita Masaru, Sasaki Atsuo T, Yano Seiji, Soga Tomoyoshi
- Journal Title
  
  Communications Biology
  
  Volume: 4 Issue: 1 Pages: 1-12
- DOI
  10.1038/s42003-021-02323-7
- NAID
  120007178465
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-19H03668, KAKENHI-PROJECT-20H03542, KAKENHI-PROJECT-19J22093, KAKENHI-PROJECT-19K07659, KAKENHI-PROJECT-17KK0199, KAKENHI-PLANNED-20H05743
[Journal Article] MAPKシグナル経路を標的とする分子標的治療2021
- Author(s)
  衣斐寛倫
- Journal Title
  
  がん分子標的治療 (Journal of Molecular Targeted Therapy for Cancer)
  
  Volume: 18 Pages: 193-198
- Data Source
  KAKENHI-PROJECT-20H03542
[Journal Article] Unmasking BCL-2 Addiction in Synovial Sarcoma by Overcoming Low NOXA2021
- Author(s)
  Fairchild Carter K.、Floros Konstantinos V.、Jacob Sheeba、Coon Colin M.、Puchalapalli Madhavi、Hu Bin、Harada Hisashi、Dozmorov Mikhail G.、Koblinski Jennifer E.、Smith Steven C.、Domson Gregory、Leverson Joel D.、Souers Andrew J.、Takebe Naoko、Ebi Hiromichi、Faber Anthony C.、Boikos Sosipatros A.
- Journal Title
  
  Cancers
  
  Volume: 13 Issue: 10 Pages: 2310-2310
- DOI
  10.3390/cancers13102310
- Peer Reviewed / Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-20H03542
[Journal Article] CIRCULATE‐Japan: Circulating tumor DNA?guided adaptive platform trials to refine adjuvant therapy for colorectal cancer2021
- Author(s)
  Taniguchi Hiroya、Nakamura Yoshiaki、Kotani Daisuke、Yukami Hiroki、Mishima Saori、Sawada Kentaro、Shirasu Hiromichi、Ebi Hiromichi、Yamanaka Takeharu、Aleshin Alexey、Billings Paul R.、Rabinowitz Matthew、Oki Eiji、Takemasa Ichiro、Kato Takeshi、Mori Masaki、Yoshino Takayuki
- Journal Title
  
  Cancer Science
  
  Volume: 112 Issue: 7 Pages: 2915-2920
- DOI
  10.1111/cas.14926
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-20H03542
[Journal Article] Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial2021
- Author(s)
  Nakamura Y、Okamoto W、Kato T、Esaki T、Kato K、Komatsu Y、Yuki S、Masuishi T、Nishina T、Ebi H、Sawada K、Taniguchi H、Fuse N、Nomura S、Fukui M、Matsuda S、Sakamoto Y、Uchigata H、Kitajima K、Kuramoto N、Asakawa T、Olsen S、Odegaard J、Sato A、Fujii S、Ohtsu A、Yoshino T
- Journal Title
  
  Nature Medicine
  
  Volume: 27 Issue: 11 Pages: 1899-1903
- DOI
  10.1038/s41591-021-01553-w
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-20H03542
[Journal Article] Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers2021
- Author(s)
  Adachi Yuta、Kimura Ryo、Hirade Kentaro、Ebi Hiromichi
- Journal Title
  
  Cancers
  
  Volume: 13 Issue: 20 Pages: 5081-5081
- DOI
  10.3390/cancers13205081
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-20H03542
[Journal Article] PTEN loss mediates clinical cross-resistance to CDK4/6 and PI3Kalpha inhibitors in breast cancer.2020
- Author(s)
  Costa C, Wang Y, Ly A, Hosono Y, Ellen M, Walmsley CS, Huynh T, Healy C, Peterson R, Yanase S, Jakubik CT, Henderson LE, Damon LJ, Timonina D, Sanidas I, Pinto CJ, Mino-Kenudson M, Stone JR, Dyson NJ, Ellisen LW, Bardia A, Ebi H, Benes CH, Engelman JA and Juric D.
- Journal Title
  
  Cancer Discovery
  
  Volume: 10 Issue: 1 Pages: 72-85
- DOI
  10.1158/2159-8290.cd-18-0830
- Peer Reviewed / Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-15KK0303
[Journal Article] BIG BANG study (EPOC1703): multicentre, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy with binimetinib, encorafenib and cetuximab in patients with BRAF non-V600E mutated metastatic colorectal cancer2020
- Author(s)
  Kotani D, Bando H, Taniguchi H, Masuishi T, Komatsu Y, Yamaguchi K, Nakajima T, Satoh T, Nishina T, Esaki T, Nomura S, Takahashi K, Iida S, Matsuda S, Motonaga S, Fuse N, Sato A, Fujii S, Ohtsu A, Ebi H, Yoshino T.
- Journal Title
  
  ESMO open
  
  Volume: 1 Issue: 1 Pages: e000624-e000624
- DOI
  10.1136/esmoopen-2019-000624
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-20H03542
[Journal Article] Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C-Mutant Non-Small Cell Lung Cancer2020
- Author(s)
  Adachi Y, Ito K, Hayashi Y, Kimura R, Tan TZ, Yamaguchi R, Ebi H.
- Journal Title
  
  Clinical Cancer Research
  
  Volume: 26 Issue: 22 Pages: 5962-5973
- DOI
  10.1158/1078-0432.ccr-20-2077
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-20H03542
[Journal Article] Japanese Society of Medical Oncology Clinical Guidelines: Molecular Testing for Colorectal Cancer Treatment, 4th edition2020
- Author(s)
  Ebi H, Bando H, Taniguchi H, Sunakawa Y, Okugawa Y, Hatanaka Y, Hosoda W, Kumamoto K, Nakatani K, Yamazaki K.
- Journal Title
  
  Cancer Science
  
  Volume: 111 Issue: 10 Pages: 3962-3969
- DOI
  10.1111/cas.14567
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-20H03542
[Journal Article] ALK Expression in Small Cell Lung Cancer2019
- Author(s)
  Kondoh Chiaki、Horio Yoshitsugu、Hayashi Yuko、Ebi Hiromichi、Hida Toyoaki、Hasegawa Yoshinori、Yatabe Yasushi
- Journal Title
  
  Histopathology
  
  Volume: in press Issue: 1 Pages: 20-28
- DOI
  10.1111/his.13842
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-16H05167, KAKENHI-PROJECT-15KK0303
[Journal Article] Evaluation of ALK fusion newly identified in colon cancer by a comprehensive genomic analysis.2019
- Author(s)
  Hosono Y, Masuishi T, Mitani S, Yamaguchi R, Kato S, Yoshino T, Ebi H.
- Journal Title
  
  JCO Precision Oncology
  
  Volume: 3 Issue: 3 Pages: 1-4
- DOI
  10.1200/po.19.00268
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-15KK0303
[Journal Article] ADAM17 selectively activates the IL‐6 trans‐signaling/ERK MAPK axis in KRAS‐addicted lung cancer2019
- Author(s)
  Saad MI, Alhayyani S, McLeod L, Liang Yu L, Alanazi M, Deswaerte V, Tang K, Jarde T, Smith JA, Prodanovic Z, Tate MD, Balic JJ, Watkins DM, Cain JE, Bozinovski S, Algar E, Kohmoto T, Ebi H, Ferlin W, Garbers C, Ruwanpura S, Sagi I, Rose-John S, Jenkins BJ
- Journal Title
  
  EMBO Molecular Medicine
  
  Volume: 11 Issue: 4
- DOI
  10.15252/emmm.201809976
- Peer Reviewed / Open Access / Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-15KK0303, KAKENHI-PROJECT-18J21308, KAKENHI-PROJECT-16K07164
[Journal Article] The ADAM17 Protease Promotes Tobacco Smoke Carcinogen-induced Lung Tumourigenesis.2019
- Author(s)
  Saad MI, McLeod L, Yu L, Ebi H, Ruwanpura S, Sagi I, Rose-John S and Jenkins BJ.
- Journal Title
  
  Carcinogenesis
  
  Volume: pii: bgz123 Issue: 4 Pages: 1-12
- DOI
  10.1093/carcin/bgz123
- Peer Reviewed / Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-15KK0303
[Journal Article] Response to Anti-EGFR Therapy in Patients with BRAF non-V600-Mutant Metastatic Colorectal Cancer.2019
- Author(s)
  20.Yaeger R, Kotani D, Mondaca S, Parikh AR, Bando H, Van Seventer EE, Taniguchi H, Zhao H, Thant CN, de Stanchina E, Rosen N, Corcoran RB, Yoshino T, Yao Z and Ebi H.
- Journal Title
  
  Clinical Cancer Research
  
  Volume: 25 Issue: 23 Pages: 7089-7097
- DOI
  10.1158/1078-0432.ccr-19-2004
- Peer Reviewed / Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-15KK0303
[Journal Article] KRAS遺伝子変異肺がんに対する分子標的治療2018
- Author(s)
  衣斐寛倫
- Journal Title
  
  最新医学
  
  Volume: 73 Pages: 983-988
- NAID
  40021632024
- Data Source
  KAKENHI-PROJECT-15KK0303
[Journal Article] RAS/MAPK系に対する治療開発と課題2018
- Author(s)
  衣斐寛倫
- Journal Title
  
  実験医学
  
  Volume: 36 Pages: 2530-2534
- Data Source
  KAKENHI-PROJECT-16K07164
[Journal Article] Japanese Society of Medical Oncology Clinical Guidelines: Molecular Testing for Colorectal Cancer Treatment, Third Edition2018
- Author(s)
  Yamazaki Kentaro、Taniguchi Hiroya、Yoshino Takayuki、Akagi Kiwamu、Ishida Hideyuki、Ebi Hiromichi、Nakatani Kaname、Muro Kei、Yatabe Yasushi、Yamaguchi Kensei、Tsuchihara Katsuya
- Journal Title
  
  Cancer Science
  
  Volume: 109 Issue: 6 Pages: 2074-2079
- DOI
  10.1111/cas.13617
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-15KK0303, KAKENHI-PROJECT-16H05167, KAKENHI-PROJECT-16K07164
[Journal Article] Increased Synthesis of MCL-1 Protein Underlies Initial Survival of EGFR-Mutant Lung Cancer to EGFR Inhibitors and Provides a Novel Drug Target2018
- Author(s)
  Song KA, Hosono Y, Turner C, Jacob S, Lochmann TL, Murakami Y, Patel NU, Ham J, Hu B, Powell KM, Coon CM, Windle B, Oya Y, Koblinski JE, Harada H, Leverson JD, Souers AJ, Hata AN, Boikos SA, Yatabe Y, Ebi H, Faber AC
- Journal Title
  
  Clinical Cancer Research
  
  Volume: 24 Issue: 22 Pages: 5658-5672
- DOI
  10.1158/1078-0432.ccr-18-0304
- Peer Reviewed / Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-15KK0303, KAKENHI-PROJECT-16H05167, KAKENHI-PROJECT-19K21295, KAKENHI-PROJECT-16K07164
[Journal Article] RAS/MAPK系に対する治療開発と課題2018
- Author(s)
  衣斐寛倫
- Journal Title
  
  実験医学
  
  Volume: 36 Pages: 2530-2534
- Data Source
  KAKENHI-PROJECT-15KK0303
[Journal Article] Distinct dependencies on receptor tyrosine kinases in the regulation of MAPK signaling between BRAF V600E and non-V600E mutant lung cancers2018
- Author(s)
  Kotani Hiroshi、Adachi Yuta、Kitai Hidenori、Tomida Shuta、Bando Hideaki、Faber Anthony C.、Yoshino Takayuki、Voon Dominic C.、Yano Seiji、Ebi Hiromichi
- Journal Title
  
  Oncogene
  
  Volume: 37 Issue: 13 Pages: 1775-1787
- DOI
  10.1038/s41388-017-0035-9
- Peer Reviewed / Open Access / Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-17K10784, KAKENHI-PUBLICLY-16H01574, KAKENHI-PROJECT-15KK0303, KAKENHI-PROJECT-16H05308, KAKENHI-PROJECT-16K07164
[Journal Article] KRAS遺伝子変異肺がんに対する分子標的治療2018
- Author(s)
  衣斐寛倫
- Journal Title
  
  最新医学
  
  Volume: 73 Pages: 983-988
- NAID
  40021632024
- Data Source
  KAKENHI-PROJECT-16K07164
[Journal Article] Epithelial-to-Mesenchymal Transition Antagonizes Response to Targeted Therapies in Lung Cancer by Suppressing BIM2017
- Author(s)
  Song Kyung-A、Ebi Hiromichi、et al. (30人中28番目）
- Journal Title
  
  Clinical Cancer Research
  
  Volume: 24 Issue: 1 Pages: 197-208
- DOI
  10.1158/1078-0432.ccr-17-1577
- Peer Reviewed / Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-16K07164, KAKENHI-PROJECT-15KK0303
[Journal Article] Resistance mediated by alternative receptor tyrosine kinases in FGFR1-amplified lung cancer2017
- Author(s)
  Adachi Yuta、Watanabe Kazuyoshi、Kita Kenji、Kitai Hidenori、Kotani Hiroshi、Sato Yuki、Inase Naohiko、Yano Seiji、Ebi Hiromichi
- Journal Title
  
  Carcinogenesis
  
  Volume: 38 Issue: 11 Pages: 1063-1072
- DOI
  10.1093/carcin/bgx091
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-16K07164, KAKENHI-PROJECT-16H05308
[Journal Article] Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO?ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS2017
- Author(s)
  Yoshino T、Arnold D、Taniguchi H、Pentheroudakis G、Yamazaki K、Xu R -H、Kim T W、Ismail F、Tan I B、Yeh K -H、Grothey A、Zhang S、Ahn J B、Mastura M Y、Chong D、Chen L -T、Kopetz S、Eguchi-Nakajima T、Ebi H、Ohtsu A、Cervantes A、Muro K、Tabernero J、Minami H、Ciardiello F、Douillard J -Y
- Journal Title
  
  Annals of Oncology
  
  Volume: 29 Issue: 1 Pages: 44-70
- DOI
  10.1093/annonc/mdx738
- Peer Reviewed / Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-16K07164
[Journal Article] Key roles of EMT for adaptive resistance to MEK inhibitor in KRAS mutant lung cancer2017
- Author(s)
  Kitai Hidenori、Ebi Hiromichi
- Journal Title
  
  Small GTPases
  
  Volume: 8 Issue: 3 Pages: 172-176
- DOI
  10.1080/21541248.2016.1210369
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-16K07164, KAKENHI-PROJECT-15KK0303
[Journal Article] Epithelial-to-mesenchymal transition defines feedback activation of receptor tyrosine kinase signaling induced by MEK inhibition in KRAS mutant lung cancer.2016
- Author(s)
  Kitai H, Ebi H, Tomida S, Floros KV, Kotani H, Adachi Y, Oizumi S, Nishimura M, Faber AC, Yano S. (Corrensponding Author)
- Journal Title
  
  Cancer Discoverty
  
  Volume: 6 Pages: 754-69
- Peer Reviewed / Acknowledgement Compliant / Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-16K07164
[Journal Article] High efficacy of third generation EGFR inhibitor AZD9291 in a　leptomeningeal carcinomatosis model with EGFR-mutant lung cancer cells2016
- Author(s)
  Nanjo S, Ebi H, Arai S, Takeuchi S, Yamada T, Mochizuki S, Okada Y, Nakada M, Murakami T, Yano S.
- Journal Title
  
  Oncotarget
  
  Volume: 7(4) Issue: 4 Pages: 3847-3856
- DOI
  10.18632/oncotarget.6758
- NAID
  120005830568
- Peer Reviewed / Acknowledgement Compliant / Open Access
- Data Source
  KAKENHI-PROJECT-26461700, KAKENHI-PROJECT-26830105, KAKENHI-PROJECT-16H05308, KAKENHI-PROJECT-26293322, KAKENHI-PROJECT-16K07164
[Journal Article] Recurrence of renal cell carcinoma diagnosed using contralateral adrenal biopsy with endoscopic ultrasound-guided fine-needle aspiration.2016
- Author(s)
  Tanimoto A, Takeuchi S, Yaegashi H, Kotani H, Kitai H, Nanjo S, Ebi H, Yamashita K, Mouri H, Ohtsubo K, Ikeda H, Yano S
- Journal Title
  
  Mol Clin Oncol.
  
  Volume: 4 Pages: 537-540
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-16K07164
[Journal Article] Lack of association between the BIM deletion polymorphism and the risk of lung cancer with and without EGFR mutations.2015
- Author(s)
  Ebi H, Yano S, et al.
- Journal Title
  
  J Thorac Oncol
  
  Volume: 10 Issue: 1 Pages: 59-66
- DOI
  10.1097/jto.0000000000000371
- Peer Reviewed / Acknowledgement Compliant / Open Access
- Data Source
  KAKENHI-PLANNED-22112010, KAKENHI-PROJECT-24390209, KAKENHI-PROJECT-25860640, KAKENHI-PROJECT-26830105
[Journal Article] Japanese Society of Medical Oncology Clinical Guidelines: RAS (KRAS/NRAS) mutation testing in colorectal cancer patients2015
- Author(s)
  Taniguchi H, Yamazaki K, Yoshino T, Muro K, Yatabe Y, Watanabe T, Ebi H, Ochiai A, Baba E, Tsuchihara K.
- Journal Title
  
  Ｃａｎｃｅｒ　Ｓｃｉｅｎｃｅ
  
  Volume: 106 Issue: 3 Pages: 324327-324327
- DOI
  10.1111/cas.12595
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-26830105
[Journal Article] Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression2015
- Author(s)
  Hiromichi Ebi, Hiroshi Kotani, Hidenori Kitai, Shigeki Nanjo, Kenji Kita, Seiji Yano, Akishi Ooi, Tiffany Huynh, Mari Mino-Kenudson, and Anthony C. Faber
- Journal Title
  
  Oncogene
  
  Volume: 未定 Issue: 27 Pages: 3587-97
- DOI
  10.1038/onc.2015.426
- Peer Reviewed / Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-25460452, KAKENHI-PROJECT-26830105, KAKENHI-PROJECT-16K07164
[Journal Article] Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer.2015
- Author(s)
  Faber AC, Ebi H, Engelman JA et al.
- Journal Title
  
  Proc. Natl. Acad. Sci. USA
  
  Volume: 112 Issue: 11
- DOI
  10.1073/pnas.1411848112
- Peer Reviewed / Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-26830105
[Journal Article] Measurement of PIP3 levels reveals an unexpected role for p110β in early adaptive responses to p110α-specific inhibitors in luminal breast cancer.2015
- Author(s)
  Costa C, Ebi H, Martini M, Beausoleil SA, Faber AC, Jakubik CT, Huang A, Wang Y, Nishtala M, Hall B, Rikova K, Zhao J, Hirsch E, Benes CH, Engelman JA.
- Journal Title
  
  Cancer Cell
  
  Volume: 27 Issue: 1 Pages: 97-108
- DOI
  10.1016/j.ccell.2014.11.007
- Peer Reviewed / Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-26830105
[Journal Article] Not just gRASping at flaws: finding vulnerabilities to develop novel therapies for treating KRAS mutant cancers.2014
- Author(s)
  Ebi H, Yano S, et al.
- Journal Title
  
  Cancer Sci
  
  Volume: 105 Issue: 5 Pages: 499-505
- DOI
  10.1111/cas.12383
- NAID
  120005830600
- Peer Reviewed / Acknowledgement Compliant / Open Access
- Data Source
  KAKENHI-PLANNED-22112010, KAKENHI-PROJECT-24390209, KAKENHI-PROJECT-26830105
[Journal Article] PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1.2013
- Author(s)
  Ebi H, Yano S, et al.
- Journal Title
  
  PNAS
  
  Volume: 110 Issue: 52 Pages: 21124-9
- DOI
  10.1073/pnas.1314124110
- Peer Reviewed
- Data Source
  KAKENHI-PLANNED-22112010, KAKENHI-PROJECT-24390209
[Patent] 特許権2015
- Inventor(s)
  衣斐寛倫、矢野聖二、北井秀典
- Industrial Property Rights Holder
  国立大学法人金沢大学
- Industrial Property Rights Type
  特許
- Industrial Property Number
  2015-227015
- Filing Date
  2015-11-19
- Data Source
  KAKENHI-PROJECT-26830105
[Presentation] KRAS 変異癌における標的治療耐性機構の克服2022
- Author(s)
  足立雄太、新津宏明、衣斐寛倫
- Organizer
  第81回日本癌学会学術総会
- Invited
- Data Source
  KAKENHI-PROJECT-20H03542
[Presentation] Relationship between circulating tumor DNA and molecular phenotype in colorectal cancer2022
- Author(s)
  衣斐寛倫
- Organizer
  第81回日本癌学会学術総会
- Invited
- Data Source
  KAKENHI-PROJECT-20H03542
[Presentation] KRAS 変異癌における標的治療耐性機構の克服2022
- Author(s)
  足立雄太、新津宏明、衣斐寛倫
- Organizer
  第81回日本癌学会
- Invited
- Data Source
  KAKENHI-PROJECT-22K19473
[Presentation] Mechanisms of resistance to RAS-targeting therapies2021
- Author(s)
  Hiromichi Ebi
- Organizer
  第19回日本臨床腫瘍学会学術集会
- Invited
- Data Source
  KAKENHI-PROJECT-20H03542
[Presentation] Perspectives for targeted therapy to colon cancer2021
- Author(s)
  Hiromichi Ebi
- Organizer
  第80回日本癌学会学術総会
- Invited
- Data Source
  KAKENHI-PROJECT-20H03542
[Presentation] RAS 変異がんに対する分子標的治療2020
- Author(s)
  衣斐寛倫
- Organizer
  日本癌学会学術総会
- Invited
- Data Source
  KAKENHI-PROJECT-20H03542
[Presentation] Targeting cancers with aberrant MAPK signal2019
- Author(s)
  Hiromichi Ebi
- Organizer
  The 24th JFCR－ISCC International Meeting
- Invited / Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-15KK0303
[Presentation] Overcome Resistance by Regulating Feedback Signaling Pathway2019
- Author(s)
  Hiromichi Ebi
- Organizer
  名古屋国際癌治療シンポジウム
- Invited / Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-15KK0303
[Presentation] 4.Overcome Resistance by Regulating Feedback Signaling Pathway2019
- Author(s)
  Hiromichi Ebi
- Organizer
  名古屋国際癌治療シンポジウム
- Invited / Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-16K07164
[Presentation] 3.Combination Therapies Targeting KRAS Mutant Lung Cancer.2018
- Author(s)
  Hiromichi Ebi
- Organizer
  The 6th JCA-AACR Special Joint Conference
- Invited / Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-16K07164
[Presentation] MEK阻害薬に対する耐性機序2018
- Author(s)
  衣斐寛倫
- Organizer
  日本肺癌学会学術総会
- Invited
- Data Source
  KAKENHI-PROJECT-16K07164
[Presentation] Intrinsic and acquired resistance to tumors aberrant MAPK signaling2018
- Author(s)
  衣斐寛倫
- Organizer
  第77回日本癌学会学術総会
- Invited
- Data Source
  KAKENHI-PROJECT-15KK0303
[Presentation] 2.Intrinsic and acquired resistance to tumors aberrant MAPK signaling、2018
- Author(s)
  衣斐寛倫
- Organizer
  第77回日本癌学会学術総会
- Invited
- Data Source
  KAKENHI-PROJECT-16K07164
[Presentation] Combination Therapies Targeting KRAS Mutant Lung Cancer.2018
- Author(s)
  Hiromichi Ebi
- Organizer
  The 6th JCA-AACR Special Joint Conference
- Invited / Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-15KK0303
[Presentation] MEK阻害薬に対する耐性機序2018
- Author(s)
  衣斐寛倫
- Organizer
  日本肺癌学会学術総会
- Invited
- Data Source
  KAKENHI-PROJECT-15KK0303
[Presentation] MAPK変異腫瘍における分子標的治療薬耐性の解明と新規治療開発2017
- Author(s)
  衣斐寛倫
- Organizer
  第21回日本がん分子標的治療学会学術集会
- Invited
- Data Source
  KAKENHI-PROJECT-16K07164
[Presentation] BRAF変異腫瘍におけるシグナル伝達系の違いを利用した新規治療戦略2017
- Author(s)
  衣斐寛倫、小谷浩、足立雄太、矢野聖二
- Organizer
  第76回日本癌学会学術総会
- Data Source
  KAKENHI-PROJECT-16K07164
[Presentation] BRAF変異腫瘍におけるシグナル伝達系の違いを利用した新規治療戦略2017
- Author(s)
  衣斐寛倫　小谷浩，足立雄太，矢野聖二
- Organizer
  第76回日本癌学会学術総会
- Data Source
  KAKENHI-PROJECT-15KK0303
[Presentation] MAPK変異腫瘍における分子標的治療薬耐性の解明と新規治療開発2017
- Author(s)
  衣斐寛倫
- Organizer
  第21回日本がん分子標的治療学会学術集会
- Invited
- Data Source
  KAKENHI-PROJECT-15KK0303
[Presentation] 上皮間葉移行に基づいたKRAS変異肺癌に対するMEK阻害薬の新規治療戦略2016
- Author(s)
  北井秀典,　衣斐寛倫,　小谷浩,　足立雄太,　冨田秀太,　大泉聡史,　西村正治,　矢野聖二
- Organizer
  日本肺癌学会学術集会
- Place of Presentation
  福岡県福岡市
- Year and Date
  2016-12-19
- Data Source
  KAKENHI-PROJECT-16K07164
[Presentation] Targeting RAS/RAF mutant cancers: Regulation of MAPK signaling is the key2016
- Author(s)
  衣斐寛倫
- Organizer
  第14回日本臨床腫瘍学会学術集会
- Place of Presentation
  兵庫県神戸市
- Year and Date
  2016-07-28
- Data Source
  KAKENHI-PROJECT-16K07164
[Presentation] EMT defines feedback activation of RTK signaling included by MEK inhibition in KRAS mutant lung cancer2016
- Author(s)
  衣斐寛倫
- Organizer
  日本癌学会学術総会
- Place of Presentation
  神奈川県横浜市
- Year and Date
  2016-10-06
- Data Source
  KAKENHI-PROJECT-16K07164
[Presentation] Feedback mechanism as a cause of resistance and therapeutic targets in molecular targeted therapy2016
- Author(s)
  衣斐寛倫
- Organizer
  第14回日本臨床腫瘍学会学術集会
- Place of Presentation
  兵庫県神戸市
- Year and Date
  2016-07-28
- Data Source
  KAKENHI-PROJECT-16K07164
[Presentation] Combinatorial approach targeting KRAS mutant cancers2015
- Author(s)
  Hiromichi Ebi
- Organizer
  The 20th JFCR－ISCC
- Place of Presentation
  Miraikan National Museum of Emerging Science and Innovation, Koto-ku, Tokyo
- Year and Date
  2015-12-09
- Invited / Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-26830105

1. YANO Seiji (30294672)

# of Collaborated Projects: 2 results

# of Collaborated Products: 3 results
2. SUZUKI Takeshi (30262075)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
3. NISHIOKA Yasuhiko (70274199)

# of Collaborated Projects: 1 results

# of Collaborated Products: 1 results
4. OHTSUBO Koshiro (60361987)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
5. 山口類 (90380675)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
6. 宮野悟 (50128104)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
7. 丸橋弘治 (20417504)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
8. PARK HEEWON (70756642)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
9. OOI Akishi

# of Collaborated Projects: 0 results

# of Collaborated Products: 1 results
10. 谷田部恭

# of Collaborated Projects: 0 results

# of Collaborated Products: 1 results
11. 樋田豊明

# of Collaborated Projects: 0 results

# of Collaborated Products: 1 results
12. 村上孝

# of Collaborated Projects: 0 results

# of Collaborated Products: 1 results
13. 冨田秀太

# of Collaborated Projects: 0 results

# of Collaborated Products: 1 results

Ebi Hiromichi 衣斐 寛倫

EBI Hiromichi 衣斐 寛倫

Research Projects

Research Products

Co-Researchers

Role of protein localization in the resistance mechanism to molecular targeted drugsPrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

Elucidation of the role of oncometabolite in the resistance mechanism of molecular targeted therapyPrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

説明可能AIによる１細胞計測大規模ネットワークデータからの知識発見技術の開発

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

Tumor agonistic and tissue specific role of BRAF mutations in cancerPrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

Develop novel therapeutics against KRAS mutant cancer by regulating PI3K and ERK signal(Fostering Joint International Research)Principal Investigator

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

Development of target therapy against KRAS mutant lung cancer stratified by EMT status.Principal Investigator

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

Development of treatment strategy against KRAS mutant cancer by targeting PI3K and ERKPrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

Study to overcome metastasis and targeted drug-resistance of lung cancer

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

Development of novel therapy targeting microenvironment in respiratory malignancy

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

[Book] 分子呼吸器病2017

Author(s)

Total Pages

Publisher

Data Source

[Book] 分子呼吸器病2017

Author(s)

Total Pages

Publisher

Data Source

[Book] 腫瘍内科2016

Author(s)

Total Pages

Publisher

Data Source

[Book] 臨床消化器内科2016

Author(s)

Total Pages

Publisher

Data Source

[Book] 日本胸部臨床2015

Ebi Hiromichi 衣斐寛倫

EBI Hiromichi 衣斐寛倫